New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT06187402
Summary
This is the first human study of an experimental drug called LM-24C5 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Melvan and Bren Simon Cancer Center
NOT_YET_RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
-
Mary Crowley Cancer Research Center
NOT_YET_RECRUITINGDallas, Texas, 75230, United States
Contact
-
Ocala Oncology
RECRUITINGOcala, Florida, 34474, United States
Contact
-
The Christ Hospital
NOT_YET_RECRUITINGCincinnati, Ohio, 45219, United States
Contact
-
University of Southern California (USC) - Norris Comprehensive Cancer Center
NOT_YET_RECRUITINGLos Angeles, California, 90089, United States
Contact
-
Virginia Cancer Specialists, P.C.
NOT_YET_RECRUITINGFairfax, Virginia, 22031, United States
Contact
Conditions
Explore the condition pages connected to this study.